{"nctId":"NCT01888497","briefTitle":"Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers","startDateStruct":{"date":"2013-07-29","type":"ACTUAL"},"conditions":["Healthy"],"count":59,"armGroups":[{"label":"Arm A","type":"EXPERIMENTAL","interventionNames":["Drug: Gabapentin"]},{"label":"Arm B","type":"EXPERIMENTAL","interventionNames":["Drug: Diphenhydramine citrate"]},{"label":"Arm C","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Triazolam"]},{"label":"Arm D","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Gabapentin","otherNames":[]},{"name":"Diphenhydramine citrate","otherNames":[]},{"name":"Triazolam","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy males and females of non-childbearing potential, 25-55 years of age\n* Valid driver's license\n\nExclusion Criteria:\n\n* Psychiatric disorder\n* Recent history of clinically significant neurological disorder, such as seizures, stroke, multiple sclerosis, or head trauma\n* Recent histroy or current treatment for sleep disorder","healthyVolunteers":true,"sex":"ALL","minimumAge":"25 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Standard Deviation of Lateral Position (SDLP)","description":"Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). SDLP was used to assess driver's ability to track their lane and was the standard deviation of lane positions through the entire drive.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.2","spread":"8.0"},{"groupId":"OG001","value":"34.2","spread":"10.0"},{"groupId":"OG002","value":"35.4","spread":"8.9"},{"groupId":"OG003","value":"47.4","spread":"12.0"}]}]}]},{"type":"SECONDARY","title":"Speed Deviation","description":"Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). Standard deviation of speed was reported in the outcome measure.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.3"},{"groupId":"OG001","value":"0.9","spread":"0.3"},{"groupId":"OG002","value":"1.0","spread":"0.3"},{"groupId":"OG003","value":"1.3","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Lane Exceedance","description":"Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). Mean lanes excursed/exceeded was reported in the outcome measure.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8","spread":"45.9"},{"groupId":"OG001","value":"46.7","spread":"58.5"},{"groupId":"OG002","value":"52.4","spread":"62.0"},{"groupId":"OG003","value":"147.7","spread":"113.6"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":58},"commonTop":["Somnolence","Nausea","Lethargy","Headache","Vision blurred"]}}}